LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Elenco Azioni・Roivant Sciences Ltd

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

29.06 2.14

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.27

Massimo

29.29

Metriche Chiave
By Trading Economics
Entrata	669M 356M
Vendite	521K 2.5M
Margine di Profitto	14,116.825
Dipendenti	721
EBITDA	-65M -354M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+28.22% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	255M 20B
Apertura precedente	26.92
Chiusura precedente	29.06

Notizie sul Sentiment di mercato

By Acuity

24%

76%

48 / 344 Classifica in Healthcare

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 giu 2026, 23:49 UTC

Discorsi di Mercato

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 giu 2026, 23:45 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 giu 2026, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 giu 2026, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 giu 2026, 20:51 UTC

Utili

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 20:09 UTC

Discorsi di Mercato

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 giu 2026, 19:36 UTC

Discorsi di Mercato

Cattle Climbs as Crude Oil Falls -- Market Talk

9 giu 2026, 19:32 UTC

Discorsi di Mercato

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 giu 2026, 19:25 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 giu 2026, 19:00 UTC

Discorsi di Mercato

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 giu 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 giu 2026, 18:47 UTC

Discorsi di Mercato

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 giu 2026, 18:37 UTC

Discorsi di Mercato

Canada's Cooling Trade With the U.S. -- Market Talk

9 giu 2026, 18:27 UTC

Discorsi di Mercato

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 giu 2026, 17:35 UTC

Discorsi di Mercato

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 giu 2026, 17:30 UTC

Discorsi di Mercato

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 giu 2026, 16:34 UTC

Discorsi di Mercato

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 giu 2026, 15:28 UTC

Discorsi di Mercato

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 giu 2026, 15:25 UTC

Discorsi di Mercato

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

28.22% in crescita

Previsioni per 12 mesi

Media 36.53 USD 28.22%

Alto 42 USD

Basso 29.29 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

48 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.